<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan R Strosberg, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H12145086"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pancreatic neuroendocrine tumors (NETs), also known as islet cell tumors, are rare neoplasms that arise in the endocrine tissues of the pancreas  (<a class="graphic graphic_picture graphicRef56960" href="/z/d/graphic/56960.html" rel="external">picture 1</a>). They can secrete a variety of peptide hormones, including insulin, gastrin, glucagon, and vasoactive intestinal peptide, resulting in myriad clinical syndromes. In modern clinical series, however, between 50 and 75 percent of pancreatic NETs are nonfunctioning (ie, unassociated with a hormonal syndrome).</p><p>This topic review will cover the classification, clinical presentation, localization, and staging of well-differentiated pancreatic NETs. A discussion of surgical management of sporadic pancreatic NETs; the clinical features, diagnostic evaluation, and treatment of high-grade gastroenteropancreatic neuroendocrine carcinomas; and specific topics that address the presentation and management of functioning pancreatic NETs and neuroendocrine neoplasms of unknown primary site are all presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15045.html" rel="external">"Surgical resection of sporadic pancreatic neuroendocrine tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p></p><p class="headingAnchor" id="H12145093"><span class="h1">CLASSIFICATION AND NOMENCLATURE</span><span class="headingEndMark"> — </span>The nomenclature of pancreatic neuroendocrine neoplasms (NENs) has evolved considerably over the last two decades. Use of the term "islet cell tumor" (which denotes the presumed origination of pancreatic NENs in the islets of Langerhans) has declined. In more recent years, the term "pancreatic neuroendocrine tumor" (NET) has been adopted by most practitioners, as well as by the American Joint Committee on Cancer (AJCC) and the World Health Organization (WHO), for well-differentiated tumors regardless of histologic grade. The term "pancreatic neuroendocrine carcinoma" (NEC) is reserved for those cases with poorly differentiated histology and a high proliferative rate  (<a class="graphic graphic_table graphicRef115945" href="/z/d/graphic/115945.html" rel="external">table 1</a>).</p><p>NENs arising at different sites within the body are classified according to their histologic features. While there are differences in terminology and grading for these tumors arising at different sites, all commonly used classification systems reflect a basic separation between more indolent, well-differentiated tumors and far more aggressive, poorly differentiated types, which behave clinically more like small cell carcinoma of the lung.</p><p>Measures of proliferative index (Ki-67 and mitotic index) are used to assign histologic grade for pancreatic NENs. Prior to 2017, well-differentiated pancreatic NETs were separated into low-grade (G1; Ki-67 index &lt;3 percent) and intermediate-grade (G2; Ki-67 index 3 to 20 percent) categories according to proliferative rate. High-grade (G3; Ki-67 index &gt;20 percent) tumors were considered equivalent to poorly differentiated carcinomas. However, it became apparent that not all G3 tumors were poorly differentiated and that some tumors, particularly those with a Ki-67 index in the 20 to 55 percent range, had relatively well-differentiated histology, relatively good prognosis (compared with poorly differentiated carcinomas), and relatively poor response to platinum-based chemotherapy. Therefore, the 2017 WHO classification of pancreatic NENs  (<a class="graphic graphic_table graphicRef115945" href="/z/d/graphic/115945.html" rel="external">table 1</a>) includes a NET G3 category (Ki-67 &gt;20 percent) that must be distinguished from the poorly differentiated pancreatic NEC category.</p><p>This subject is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on '2010 and 2019 World Health Organization classification'</a>.)</p><p class="headingAnchor" id="H6984431"><span class="h2">Functionality and nomenclature</span><span class="headingEndMark"> — </span>Functionality also impacts nomenclature. Pancreatic NETs that are functioning (hormone secreting) are classified according to the predominant hormone they secrete and the resulting clinical syndrome. Nearly all functioning NENs are well-differentiated NETs (see  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Functionality and nomenclature'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>An insulin-producing pancreatic NET causing episodic hypoglycemia is considered to be an insulinoma. (See  <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology"</a> and  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A gastrin-producing tumor associated with Zollinger-Ellison syndrome is termed a gastrinoma. (See  <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other functioning pancreatic NETs that secrete glucagon (glucagonomas), somatostatin (somatostatinomas), or vasoactive intestinal polypeptide (VIPomas) are quite rare, with an estimated annual incidence of approximately 1 in 10 million. (See  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p>Of note, immunohistochemical staining is not a defining criterion for tumor classification. For example, if a tumor stains for gastrin but does not produce symptoms of Zollinger-Ellison syndrome, it is not considered a gastrinoma.</p><p>Although functionality may impact prognosis (eg, insulinomas are generally indolent tumors), the biologic behavior of most functioning pancreatic NETs is defined by the grade and stage of the tumor, as it is with nonfunctioning tumors. Thus, the pathologic diagnosis of a functioning pancreatic NET should be the same as for a nonfunctioning NET (ie, well-differentiated or poorly differentiated NET), with the descriptive functional designation appended to the diagnosis where there is knowledge of a clinical syndrome. </p><p class="headingAnchor" id="H4808918"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Pancreatic neuroendocrine tumors (NETs) are overall rare; they have an incidence of ≤1 case per 100,000 individuals per year and account for 1 to 2 percent of all pancreatic tumors [<a href="#rid1">1-3</a>]. Pancreatic NETs represent less than 3 percent of primary pancreatic neoplasms [<a href="#rid4">4</a>]. Incidence rates have been increasing in the United States and elsewhere over the last two decades, but it is likely that this is mainly related to increased detection of asymptomatic disease on cross-sectional imaging and endoscopy done for other reasons [<a href="#rid2">2,3</a>].</p><p>Although they may manifest at any age, they most often occur in the fourth to sixth decades of life.</p><p>Most pancreatic NETs are sporadic, but they can be associated with hereditary endocrinopathies, including multiple endocrine neoplasia type I (MEN1), von Hippel-Lindau (VHL) syndrome, neurofibromatosis type I (NF1), and tuberous sclerosis  (<a class="graphic graphic_table graphicRef70019" href="/z/d/graphic/70019.html" rel="external">table 2</a>). Approximately 80 to 100 percent of patients with MEN1, up to 20 percent of patients with VHL, 10 percent of patients with NF1, and 1 percent of patients with tuberous sclerosis will develop a pancreatic NET within their lifetime [<a href="#rid5">5</a>]. Importantly, patients who develop a pancreatic NET in the context of an inherited syndrome must be considered separately with regard to prognosis, as these tumors tend to be associated with a more indolent course than are sporadic tumors. Furthermore, specific treatments may also be available that are not useful for treatment of sporadic tumors (eg, the hypoxia-inducible factor 2 alpha inhibitor <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">belzutifan</a> for VHL-associated pancreatic NETs). (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Pancreatic tumors'</a> and  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p>Other potential risk factors for pancreatic NETs include smoking (albeit with weak evidence) [<a href="#rid6">6</a>], diabetes (although the cause versus effect relationship is not clear) [<a href="#rid6">6-9</a>], and a previous history of chronic pancreatitis [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H24623092"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of pancreatic neuroendocrine tumors (NETs) has evolved in more recent years. Up until two decades ago, most pancreatic NETs were described as functioning and were detected following diagnostic evaluation of a hormonal syndrome. In contrast, more recent clinical series describe the majority (between 50 and 85 percent) of pancreatic NETs as nonfunctioning [<a href="#rid10">10-18</a>]. </p><p class="headingAnchor" id="H7452147"><span class="h2">Functioning tumors</span><span class="headingEndMark"> — </span>The clinical presentation of specific functional tumors is addressed in detail elsewhere and is outlined in the table  (<a class="graphic graphic_table graphicRef111380" href="/z/d/graphic/111380.html" rel="external">table 3</a>). In brief:</p><p class="bulletIndent1"><span class="glyph">●</span>Insulinomas typically present with episodic hypoglycemia, which may cause confusion, visual change, unusual behavior, palpitations, diaphoresis, and tremulousness. Amnesia for hypoglycemia is common. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma", section on 'Symptoms and misdiagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrinomas typically present with peptic ulcer disease; diarrhea can also be a prominent feature. (See  <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical syndrome classically associated with glucagonoma includes necrolytic migratory erythema, cheilitis, diabetes mellitus, anemia, weight loss, diarrhea, venous thrombosis, and neuropsychiatric symptoms. (See  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The main clinical features of VIPoma syndrome are watery diarrhea, hypokalemia, and hypochlorhydria. (See  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Clinical features'</a>.)</p><p></p><p>Tumors presenting with a specific hormonal syndrome can develop additional syndromes subsequently due to secretion of more than one hormone [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H7452214"><span class="h2">Nonfunctioning tumors</span><span class="headingEndMark"> — </span>Although nonfunctioning pancreatic NETs do secrete a number of substances, such as chromogranins, neuron-specific enolase, pancreatic polypeptide, and ghrelin, they do not present clinically with a hormonal syndrome as compared with their functional counterparts. As a result, they often present later in the course of the disease with symptoms of local compression or metastatic disease [<a href="#rid20">20-22</a>]. However, mean tumor diameter has decreased in the last two decades, attributed to the increased use of cross-sectional imaging, and a larger percentage of tumors (40 and 50 percent of nonmetastatic pancreatic NETs in two series [<a href="#rid20">20,23</a>]) are now detected incidentally in asymptomatic patients who undergo diagnostic evaluations for unrelated conditions.</p><p>Occasionally, patients with tumors that appear to be nonfunctional develop symptoms of hormone secretion later in their disease course [<a href="#rid19">19</a>].</p><p>When symptomatic, the most common presenting symptoms of a nonfunctioning pancreatic NET are abdominal pain (35 to 78 percent), weight loss (20 to 35 percent), and anorexia and nausea (45 percent) [<a href="#rid24">24-27</a>]. Less frequent signs include obstructive jaundice (17 to 50 percent), intra-abdominal hemorrhage (4 to 20 percent), or a palpable mass (7 to 40 percent). Symptoms may also be attributable to metastatic disease. In a variety of published reports, between 32 and 73 percent of cases are metastatic at diagnosis [<a href="#rid3">3,12,28-30</a>].</p><p class="headingAnchor" id="H2044475793"><span class="h2">Metastatic disease</span><span class="headingEndMark"> — </span>Uncommonly, patients present with metastatic NET and an unknown primary site. The most common site of metastatic disease involvement for pancreatic NET is the liver [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site", section on 'Evaluation and management'</a>.)</p><p class="headingAnchor" id="H12145100"><span class="h1">IMAGING STUDIES FOR DISEASE LOCALIZATION</span></p><p class="headingAnchor" id="H4809019"><span class="h2">Overview of the diagnostic approach</span><span class="headingEndMark"> — </span>The diagnostic approach to a patient with a suspected pancreatic neuroendocrine tumor (NET) depends on the clinical scenario:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a biopsy-proven pancreatic NET require appropriate radiographic staging studies in order to determine the extent of disease spread in order to plan appropriate treatment. In some cases, a patient may present with confirmed metastatic disease (most often in the liver; other less common sites include retroperitoneal lymph nodes and bone [<a href="#rid32">32</a>]), and the diagnostic approach focuses on identifying both the extent of disease spread and the likely primary site of disease. In patients with either metastatic or nonmetastatic disease, cross-sectional imaging studies, such as multiphasic computed tomography (CT) scan or magnetic resonance imaging (MRI), are indicated. Imaging should focus on the abdomen; the value of chest imaging is questionable. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnostic imaging using radiolabeled somatostatin analogs is recommended for most patients. Uptake of radiolabeled somatostatin analogs is predictive of a clinical response to therapy with somatostatin analogs and peptide receptor radionuclide therapy, and it can assist in identifying an otherwise occult primary site. Where available, functional imaging with <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> (68-Ga DOTATATE) positron emission tomography (PET)/CT is preferred over indium-111 (111-In) pentetreotide (OctreoScan) due to its greater sensitivity [<a href="#rid33">33</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Occasionally, patients present with a hormonal syndrome suggestive of a pancreatic NET (such as hypoglycemia with confirmed hyperinsulinemia on a monitored fast) but lack evidence of disease on conventional imaging. These patients may require highly specialized localizing evaluations that may include endoscopic ultrasonography (EUS) or arterial stimulation with venous sampling (ASVS). The combined use of conventional imaging and endoscopic studies for an occult hormonally functioning pancreatic NET (such as a subcentimeter insulinoma) has improved the sensitivity of preoperative detection to nearly 100 percent [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma", section on 'Tumor localization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In rare cases where there is strong clinical and biochemical evidence for an occult pancreatic NET that is undetectable on EUS, we recommend arterial stimulation with transhepatic portal venous sampling (THPVS) if expertise in this technique is available. (See <a class="local">'Arterial stimulation with venous sampling'</a> below.)</p><p></p><p>The following sections will review the data on the utility of the available imaging techniques in patients with pancreatic NETs.</p><p class="headingAnchor" id="H12145107"><span class="h2">Computed tomography</span><span class="headingEndMark"> — </span>CT scans are noninvasive and readily available. Helical (spiral), multiphasic, contrast-enhanced CT is recommended for evaluation of patients with pancreatic NETs. </p><p>Most NETs are highly vascular, and liver metastases may appear isodense with the liver on a noncontrasted study. Following the injection of intravenous contrast, pancreatic NETs often enhance with iodinated contrast during the early arterial phase (approximately 20 seconds after contrast injection), with washout during the portal venous imaging phase (approximately 70 seconds after contrast injection) [<a href="#rid35">35</a>]. In addition, arterial phase and portal venous phase sequences can be used to maximize the conspicuity of liver metastases compared with the surrounding normal liver parenchyma  (<a class="graphic graphic_diagnosticimage graphicRef52935" href="/z/d/graphic/52935.html" rel="external">image 1</a>) [<a href="#rid36">36</a>]. </p><p>CT scans are highly accurate for detecting primary pancreatic NETs; using modern multiphase imaging techniques, sensitivity is &gt;80 percent [<a href="#rid36">36-38</a>]. Tumors as small as 4 mm have been visualized with CT scanning; however, sensitivity is decreased for tumors smaller than 2 cm in diameter compared with larger tumors [<a href="#rid37">37</a>]. Small tumors can often appear as rounded, enhancing vascular lesions  (<a class="graphic graphic_diagnosticimage graphicRef69231" href="/z/d/graphic/69231.html" rel="external">image 2</a>); others may be hypodense or cystic  (<a class="graphic graphic_diagnosticimage graphicRef62453" href="/z/d/graphic/62453.html" rel="external">image 3</a>).</p><p>Symptomatic but nonfunctioning tumors, VIPomas, and glucagonomas are usually large (&gt;3 cm) at the time of diagnosis. The sensitivity of contrast-enhanced CT for these tumors approaches 100 percent, and it is considered the imaging study of choice [<a href="#rid39">39,40</a>].</p><p class="headingAnchor" id="H12145114"><span class="h2">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>On MRI, pancreatic NETs are typically characterized by low signal intensity on T1-weighted images  (<a class="graphic graphic_diagnosticimage graphicRef59487" href="/z/d/graphic/59487.html" rel="external">image 4</a>) and by high signal intensity on T2-weighted images  (<a class="graphic graphic_diagnosticimage graphicRef72303" href="/z/d/graphic/72303.html" rel="external">image 5</a>). Early series examining the role of MRI for the detection of NETs were disappointing. However, with the advent of newer techniques, such as short tau inversion recovery (STIR) sequences, sensitivity has improved substantially [<a href="#rid41">41-43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 28 consecutive patients with a clinically suspected functioning pancreatic NET, MRI detected a pancreatic NET in 17 of 20 patients in whom it was done (sensitivity 85 percent) [<a href="#rid41">41</a>]. Specificity was 100 percent, and the positive and negative predictive values were 100 and 73 percent, respectively. In this study, the gold standard for diagnosis of a pancreatic NET was either resection (n = 19) or clinical follow-up for at least a year.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 64 patients with metastatic NETs, multiphasic MRI detected more hepatic lesions than either contrast-enhanced CT or somatostatin receptor scintigraphy [<a href="#rid44">44</a>]. As a result of this greater sensitivity for liver metastases, some clinicians prefer MRI over CT for assessing the status of the liver [<a href="#rid43">43</a>]. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Cross-sectional imaging'</a>.)</p><p></p><p>As with CT scans, early arterial phase imaging following the injection of gadolinium contrast is critical for the detection of small hypervascular liver metastases. In a study of 37 patients with liver metastases from gastroenteropancreatic NETs, the most sensitive sequences for detection of liver metastases were hepatic arterial phase and fast spin-echo T2-weighed images  (<a class="graphic graphic_diagnosticimage graphicRef72303" href="/z/d/graphic/72303.html" rel="external">image 5</a>) [<a href="#rid38">38</a>]. </p><p class="headingAnchor" id="H12145121"><span class="h2">Endoscopic ultrasonography</span><span class="headingEndMark"> — </span>EUS provides high-resolution imaging of the pancreas, and it can detect lesions as small as 2 to 3 mm in diameter  (<a class="graphic graphic_diagnosticimage graphicRef74947" href="/z/d/graphic/74947.html" rel="external">image 6</a>). Studies of EUS for detecting pancreatic NETs suggest high sensitivity for tumor detection [<a href="#rid34">34,37,42,43,45-49</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of 17 cohort studies (612 patients), when it was performed, EUS identified pancreatic NETs in 97 percent of cases [<a href="#rid49">49</a>]. When the analysis was limited to cases where the pancreatic NET was not detected by CT with or without other modalities, a pancreatic NET was diagnosed solely by EUS in 28 percent of cases. Studies in which multidetector CT and/or spiral CT scans were known to have been performed before EUS noted a smaller incremental benefit for EUS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report, EUS was more sensitive than either CT or transabdominal ultrasonography for detection and localization of pancreatic NETs in patients with multiple endocrine neoplasia type 1 (MEN1) syndrome [<a href="#rid48">48</a>]. In this report, sensitivity for tumors less than 6 mm in diameter was poor, as determined by inspection of resected specimens by pathologists. However, others suggest acceptable reproducibility for EUS in detecting small pancreatic NETs in patients with MEN1 [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">Although routine screening of asymptomatic patients with MEN1 with EUS has been recommended, this is a controversial area, and the optimal screening strategy in these patients remains uncertain. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Nonfunctioning pancreatic tumors'</a> and  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Monitoring for MEN1-associated tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EUS has also proven to be a useful tool for identifying pancreatic NETs such as gastrinomas that arise in the duodenal wall and have a high frequency of metastasis to the peripancreatic lymph nodes [<a href="#rid51">51</a>]. Duodenal gastrinomas are notoriously difficult to localize by CT.</p><p></p><p>Another benefit of EUS is that EUS-guided fine needle aspiration biopsy can often provide a nonoperative histologic diagnosis of pancreatic NET [<a href="#rid51">51-53</a>]. (See  <a class="medical medical_review" href="/z/d/html/2656.html" rel="external">"Endoscopic ultrasound-guided fine needle aspiration in the gastrointestinal tract"</a>.)</p><p>EUS is limited by the requirement of a highly skilled endoscopist and by its inability to consistently visualize the pancreatic tail. Nevertheless, this technique has proven useful for the localization of primary pancreatic NETs in patients without metastatic disease.</p><p class="headingAnchor" id="H12145128"><span class="h2">Somatostatin-receptor-based imaging</span><span class="headingEndMark"> — </span>Most well-differentiated NETs express high levels of somatostatin receptors and can therefore be imaged with radiolabeled somatostatin analogs. These scans allow for whole-body imaging. They also provide information on somatostatin receptor expression, which has important therapeutic implications regarding use of cold and radiolabeled somatostatin analogs. The first imaging technique to visualize somatostatin-receptor-expressing tumors used 111-In pentetreotide to produce a scintigraphic image (OctreoScan). The accuracy of 111-In pentetreotide improved with the addition of single-photon emission computed tomography (SPECT) to planar imaging  (<a class="graphic graphic_diagnosticimage graphicRef72923" href="/z/d/graphic/72923.html" rel="external">image 7</a>) [<a href="#rid54">54,55</a>].</p><p>Several PET tracers for somatostatin receptor imaging have emerged (such as 68-Ga DOTATATE, 68-Ga DOTATOC, and <a class="drug drug_general" data-topicid="129471" href="/z/d/drug information/129471.html" rel="external">copper Cu-64 DOTATATE</a>), which, in combination with integrated PET/CT, improve the detection and staging of NETs over older methods of somatostatin receptor imaging such as OctreoScan [<a href="#rid33">33,56-58</a>]. These novel PET modalities offer higher spatial resolution than conventional 111-In pentetreotide scanning and are associated with improved sensitivity for detection of small lesions, including occult primary tumors  (<a class="graphic graphic_diagnosticimage graphicRef81388" href="/z/d/graphic/81388.html" rel="external">image 8</a>). In our view (and that of others [<a href="#rid59">59</a>]), 68-Ga DOTATATE, 68-Ga DOTATOC, or 64-Cu DOTATATE PET/CT, where available, is preferred over conventional 111-In pentetreotide scanning for most NETs, especially for tumor localization in the setting of metastatic disease and an unknown primary site. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site", section on 'Initial workup'</a> and  <a class="medical medical_review" href="/z/d/html/2516.html" rel="external">"Diagnosis and staging of small bowel neoplasms", section on 'Somatostatin receptor-based imaging'</a>.)</p><p>The affinity of both 111-In pentetreotide and 68-Ga DOTATATE/68-Ga DOTATOC/64-Cu DOTATATE is highest for subtype 2 somatostatin receptors (SSTR2). Insulinomas, which are the most frequent type of functioning pancreatic NET, express relatively scant levels of SSTR2 and may be less likely to be detected with these scans [<a href="#rid60">60-63</a>].</p><p>Poorly differentiated neuroendocrine carcinomas  (<a class="graphic graphic_table graphicRef115945" href="/z/d/graphic/115945.html" rel="external">table 1</a>) also express low somatostatin receptor levels and are unlikely to be detected. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma", section on 'Diagnosis and staging'</a> and  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma", section on 'Tumor localization'</a> and  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'Radiographic studies'</a>.)</p><p class="headingAnchor" id="H12145135"><span class="h2">Arterial stimulation with venous sampling</span><span class="headingEndMark"> — </span>For rare cases in which radiographically occult, hormonally functional tumors elude detection by conventional imaging modalities, invasive approaches may be employed to localize tumors to a particular region of the pancreas for treatment planning purposes (eg, tail, body/neck, head/uncinate). These include THPVS and ASVS [<a href="#rid39">39,45</a>]. These procedures have become relatively obsolete given the improved sensitivity of preoperative imaging, especially 68-Ga DOTATATE PET and EUS.</p><p class="headingAnchor" id="H12145142"><span class="h2">Intraoperative localization techniques</span><span class="headingEndMark"> — </span>Intraoperative ultrasonography allows high-resolution examination of the pancreas. When combined with palpation of the organ, the sensitivity for tumor detection ranges from 83 to 100 percent [<a href="#rid39">39,64,65</a>]. Intraoperative transillumination has equivalent efficacy (sensitivity 83 percent) for the localization of duodenal wall gastrinomas [<a href="#rid64">64</a>].</p><p>Neither intraoperative ultrasonography nor illumination should replace preoperative imaging; they may be used as adjuncts to intraoperative palpation in patients who still have a suspected hormone-secreting pancreatic NET that cannot be identified or localized preoperatively.</p><p class="headingAnchor" id="H24623272"><span class="h2">Laboratory diagnostics</span><span class="headingEndMark"> — </span>A variety of peptide markers, including chromogranin A (CgA) and pancreatic polypeptide (PP), may be used in the follow-up of patients with pancreatic NETs. However, due to suboptimal sensitivity and specificity (particularly for CgA in the setting of proton pump inhibitor use), the value of routine tumor marker measurement has been questioned. Guidelines from the National Comprehensive Cancer Network (NCCN) consider assay of either CgA or PP for any pancreatic NET to represent a class 3 recommendation (there is major disagreement within the guidelines panel that the intervention is appropriate).</p><p class="headingAnchor" id="H24623346"><span class="h3">Functioning tumors</span><span class="headingEndMark"> — </span>Specific hormones secreted by functional tumors (ie, insulin, proinsulin, glucagon, gastrin, vasoactive intestinal polypeptide) can be measured and correlated with hormonal symptoms. Hormone levels also correspond to changes in tumor burden and can therefore serve as specific tumor markers. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'Serum glucagon'</a> and  <a class="medical medical_review" href="/z/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Hormones associated with pancreatic NETs'</a>.)</p><p class="headingAnchor" id="H900337996"><span class="h3">Nonfunctioning tumors</span><span class="headingEndMark"> — </span>We do not test nonspecific panels of hormone levels or nonhormonal tumor biomarkers such as CgA for patients with nonfunctioning tumors, which account for the majority of pancreatic NETs. (See  <a class="medical medical_review" href="/z/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H26599949"><span class="h1">STAGING SYSTEM</span><span class="headingEndMark"> — </span>Pancreatic neuroendocrine tumors (NETs) are staged using the combined American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system, which is based on the definitions proposed by the European Neuroendocrine Tumor Society (ENETS) [<a href="#rid66">66</a>]. These staging systems are highly prognostic for both relapse-free and overall survival [<a href="#rid67">67-69</a>].</p><p>The newest release of the tumor, node, metastasis (TNM) staging classification of the AJCC/UICC (eighth edition, 2017) has a staging system for pancreatic NETs  (<a class="graphic graphic_table graphicRef111355" href="/z/d/graphic/111355.html" rel="external">table 4</a>) that is separate from that used for exocrine pancreatic tumors for the first time [<a href="#rid70">70</a>]. Compared with earlier versions, it also incorporates the ENETS definitions for T stage and its prognostic stage groupings. A further modification of this combined ENETS/AJCC classification that may provide even better prognostic discrimination has been proposed based on an analysis of data from two large databases [<a href="#rid71">71</a>]. Importantly, this staging system does not apply to high-grade, poorly differentiated neuroendocrine carcinomas; these tumors are staged according to the classification for exocrine pancreatic cancer  (<a class="graphic graphic_table graphicRef111135" href="/z/d/graphic/111135.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H4208037330"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H12145156"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification and nomenclature</strong> – The nomenclature of pancreatic neuroendocrine neoplasms (NENs) has evolved considerably over the last two decades. (See <a class="local">'Classification and nomenclature'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of the term "islet cell tumor" (which denotes the presumed origination of pancreatic NENs in the islets of Langerhans) has declined, and the term "pancreatic neuroendocrine tumor" (NET) has been adopted by most practitioners, the American Joint Committee on Cancer (AJCC) and the World Health Organization (WHO), for well-differentiated tumors regardless of histologic grade.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The term "pancreatic neuroendocrine carcinoma" is reserved for those cases with poorly differentiated histology and a high proliferative/mitotic rate  (<a class="graphic graphic_table graphicRef115945" href="/z/d/graphic/115945.html" rel="external">table 1</a>). (See <a class="local">'Classification and nomenclature'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Previously, most pancreatic NETs were functioning and detected following diagnostic evaluation of a hormonal syndrome. More recent clinical series describe the majority (50 to 85 percent) as nonfunctioning. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging and disease localization</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cross-sectional imaging with multiphasic CT or MRI is highly sensitive for identification of primary pancreatic NETs as well as liver metastases. Early arterial phase imaging is particularly valuable for detection of hypervascular primary tumors and liver metastases. (See <a class="local">'Computed tomography'</a> above and <a class="local">'Magnetic resonance imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Somatostatin receptor-based imaging offers whole-body imaging and functional information regarding tumoral expression of somatostatin receptors.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Where available, functional imaging with <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> (68-Ga DOTATATE), Ga-68 DOTATOC, or Cu-64 DOTATATE positron emission tomography (PET)/CT is preferred over indium-111 (111-In) pentetreotide (OctreoScan) due to the greater sensitivity of these radiotracers.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The sensitivity of somatostatin-receptor-based imaging may be lower for the detection of insulinomas and poorly differentiated or high-grade tumors. (See <a class="local">'Somatostatin-receptor-based imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endoscopic ultrasonography (EUS) is highly sensitive for detection of occult, subcentimeter pancreatic NETs and plays an important role in the evaluation of patients with functional NETs that are undetectable using conventional imaging techniques. Through endoscopic fine needle aspiration biopsy, EUS also offers the ability to obtain a nonoperative histopathologic diagnosis. (See <a class="local">'Endoscopic ultrasonography'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients presenting with hormonal syndromes such as hypoglycemia or Zollinger-Ellison syndrome, the diagnostic modalities listed above (CT, MRI, somatostatin-receptor-based imaging, EUS) can detect nearly 100 percent of pancreatic NETs. As a result, invasive localizing techniques (such as arterial stimulation with venous sampling [ASVS]) are rarely necessary in modern practice. (See <a class="local">'Arterial stimulation with venous sampling'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Our approach to patients with suspected or biopsy-proven NETs is as follows (see <a class="local">'Overview of the diagnostic approach'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who present with hormonal syndromes suspicious for a pancreatic NET but who lack evidence of disease on conventional cross-sectional imaging, we recommend EUS. EUS with fine needle aspiration can also be used to establish a pathologic diagnosis, particularly in patients with early stage disease.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who present with a biopsy-proven well-differentiated NET in the pancreas, we recommend helical triple-phase CT (arterial phase, portal venous phase, noncontrast) or multiphasic contrast-enhanced MRI of the abdomen to stage the extent of disease. If the results would potentially change management or the treatment plan, we perform somatostatin receptor-based imaging in order to assess for somatostatin receptor expression and evaluate for extra-abdominal (predominantly bone) metastases. Where available, functional imaging with 68-Ga DOTATATE, 68-Ga DOTATOC, or 64-Cu DOTATATE PET/CT is preferred over 111-In pentetreotide (OctreoScan) due to its greater sensitivity.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In rare cases where there is strong clinical and biochemical evidence for an occult pancreatic NET that is undetectable on EUS, we recommend arterial stimulation with hepatic venous sampling if expertise in this technique is available. (See <a class="local">'Arterial stimulation with venous sampling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – Pancreatic NETs are staged using the combined AJCC/Union for International Cancer Control (UICC) staging system  (<a class="graphic graphic_table graphicRef111355" href="/z/d/graphic/111355.html" rel="external">table 4</a>) which is separate from that used for exocrine pancreatic tumors. (See <a class="local">'Staging system'</a> above.)</p><p></p><p class="headingAnchor" id="H153430370"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Stephen Goldfinger, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Klimstra DS. Nonductal neoplasms of the pancreas. Mod Pathol 2007; 20 Suppl 1:S94.</a></li><li><a class="nounderline abstract_t">Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121:589.</a></li><li><a class="nounderline abstract_t">Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3:1335.</a></li><li><a class="nounderline abstract_t">Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1766.</a></li><li><a class="nounderline abstract_t">Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469.</a></li><li><a class="nounderline abstract_t">Leoncini E, Carioli G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol 2016; 27:68.</a></li><li><a class="nounderline abstract_t">Capurso G, Falconi M, Panzuto F, et al. Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. Am J Gastroenterol 2009; 104:3034.</a></li><li><a class="nounderline abstract_t">Hassan MM, Phan A, Li D, et al. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer 2008; 123:867.</a></li><li><a class="nounderline abstract_t">Halfdanarson TR, Bamlet WR, McWilliams RR, et al. Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study. Pancreas 2014; 43:1219.</a></li><li class="breakAll">Solcia E, Kloppel G, Sobin LH.. Histological typing on endocrine tumors. In: WHO International Classification of Tumors, 2nd ed, Springer, Berlin, Germany 2000.</li><li><a class="nounderline abstract_t">Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20:2633.</a></li><li><a class="nounderline abstract_t">Zerbi A, Falconi M, Rindi G, et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol 2010; 105:1421.</a></li><li><a class="nounderline abstract_t">Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19:1727.</a></li><li><a class="nounderline abstract_t">Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84:196.</a></li><li><a class="nounderline abstract_t">Ito T, Tanaka M, Sasano H, et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007; 42:497.</a></li><li><a class="nounderline abstract_t">Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083.</a></li><li><a class="nounderline abstract_t">Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2011; 61:113.</a></li><li><a class="nounderline abstract_t">Kasumova GG, Tabatabaie O, Eskander MF, et al. National Rise of Primary Pancreatic Carcinoid Tumors: Comparison to Functional and Nonfunctional Pancreatic Neuroendocrine Tumors. J Am Coll Surg 2017; 224:1057.</a></li><li><a class="nounderline abstract_t">de Mestier L, Hentic O, Cros J, et al. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. Ann Intern Med 2015; 162:682.</a></li><li><a class="nounderline abstract_t">Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 2007; 142:347.</a></li><li><a class="nounderline abstract_t">Li J, Luo G, Fu D, et al. Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors. Med Oncol 2011; 28:1027.</a></li><li><a class="nounderline abstract_t">Nomura N, Fujii T, Kanazumi N, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg 2009; 16:639.</a></li><li><a class="nounderline abstract_t">Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol 2012; 19:2932.</a></li><li><a class="nounderline abstract_t">Cheslyn-Curtis S, Sitaram V, Williamson RC. Management of non-functioning neuroendocrine tumours of the pancreas. Br J Surg 1993; 80:625.</a></li><li><a class="nounderline abstract_t">Madura JA, Cummings OW, Wiebke EA, et al. Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg 1997; 63:573.</a></li><li><a class="nounderline abstract_t">Matthews BD, Heniford BT, Reardon PR, et al. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas. Am Surg 2000; 66:1116.</a></li><li><a class="nounderline abstract_t">Chu QD, Hill HC, Douglass HO Jr, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9:855.</a></li><li><a class="nounderline abstract_t">Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005; 16:1806.</a></li><li><a class="nounderline abstract_t">Pape UF, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113:256.</a></li><li><a class="nounderline abstract_t">Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21:1794.</a></li><li><a class="nounderline abstract_t">Riihimäki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016; 139:2679.</a></li><li><a class="nounderline abstract_t">Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas 2009; 38:255.</a></li><li><a class="nounderline abstract_t">Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.</a></li><li><a class="nounderline abstract_t">Nikfarjam M, Warshaw AL, Axelrod L, et al. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 2008; 247:165.</a></li><li><a class="nounderline abstract_t">Paulson EK, McDermott VG, Keogan MT, et al. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 1998; 206:143.</a></li><li><a class="nounderline abstract_t">Legmann P, Vignaux O, Dousset B, et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998; 170:1315.</a></li><li><a class="nounderline abstract_t">Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011; 73:691.</a></li><li><a class="nounderline abstract_t">Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003; 180:121.</a></li><li><a class="nounderline abstract_t">King CM, Reznek RH, Dacie JE, Wass JA. Imaging islet cell tumours. Clin Radiol 1994; 49:295.</a></li><li><a class="nounderline abstract_t">Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145:276.</a></li><li><a class="nounderline abstract_t">Thoeni RF, Mueller-Lisse UG, Chan R, et al. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000; 214:483.</a></li><li><a class="nounderline abstract_t">Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26.</a></li><li><a class="nounderline abstract_t">Pisegna JR, Doppman JL, Norton JA, et al. Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38:1318.</a></li><li><a class="nounderline abstract_t">Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23:70.</a></li><li><a class="nounderline abstract_t">Vinik AI, Delbridge L, Moattari R, et al. Transhepatic portal vein catheterization for localization of insulinomas: a ten-year experience. Surgery 1991; 109:1.</a></li><li><a class="nounderline abstract_t">Rösch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326:1721.</a></li><li><a class="nounderline abstract_t">Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000; 95:2271.</a></li><li><a class="nounderline abstract_t">Hellman P, Hennings J, Akerström G, Skogseid B. Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. Br J Surg 2005; 92:1508.</a></li><li><a class="nounderline abstract_t">James PD, Tsolakis AV, Zhang M, et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc 2015; 81:848.</a></li><li><a class="nounderline abstract_t">Kann PH, Kann B, Fassbender WJ, et al. Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging. Exp Clin Endocrinol Diabetes 2006; 114:361.</a></li><li><a class="nounderline abstract_t">Cadiot G, Lebtahi R, Sarda L, et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Gastroenterology 1996; 111:845.</a></li><li><a class="nounderline abstract_t">Chatzipantelis P, Salla C, Konstantinou P, et al. Endoscopic ultrasound-guided fine-needle aspiration cytology of pancreatic neuroendocrine tumors: a study of 48 cases. Cancer 2008; 114:255.</a></li><li><a class="nounderline abstract_t">Atiq M, Bhutani MS, Bektas M, et al. EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci 2012; 57:791.</a></li><li><a class="nounderline abstract_t">Schillaci O, Corleto VD, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2:S186.</a></li><li><a class="nounderline abstract_t">Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59:565.</a></li><li><a class="nounderline abstract_t">Crown A, Rocha FG, Raghu P, et al. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. J Surg Oncol 2020; 121:480.</a></li><li><a class="nounderline abstract_t">Johnbeck CB, Knigge U, Loft A, et al. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. J Nucl Med 2017; 58:451.</a></li><li><a class="nounderline abstract_t">Pfeifer A, Knigge U, Binderup T, et al. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. J Nucl Med 2015; 56:847.</a></li><li><a class="nounderline abstract_t">Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59:66.</a></li><li><a class="nounderline abstract_t">Zimmer T, Stölzel U, Bäder M, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996; 39:562.</a></li><li><a class="nounderline abstract_t">Fjällskog ML, Ludvigsen E, Stridsberg M, et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20:59.</a></li><li><a class="nounderline abstract_t">Kimura N, Pilichowska M, Date F, et al. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 1999; 5:3483.</a></li><li><a class="nounderline abstract_t">Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440:461.</a></li><li><a class="nounderline abstract_t">Frucht H, Norton JA, London JF, et al. Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study. Gastroenterology 1990; 99:1622.</a></li><li><a class="nounderline abstract_t">Huai JC, Zhang W, Niu HO, et al. Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound. Am J Surg 1998; 175:18.</a></li><li><a class="nounderline abstract_t">Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 2012; 256:321.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.</a></li><li><a class="nounderline abstract_t">Cho JH, Ryu JK, Song SY, et al. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. Pancreas 2016; 45:941.</a></li><li class="breakAll">Bergsland EK, Woltering EA, Rindo G. Neuroendocrine tumors of the pancreas. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.407. Corrected at 4th printing, 2018.</li><li><a class="nounderline abstract_t">Luo G, Javed A, Strosberg JR, et al. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol 2017; 35:274.</a></li></ol></div><div id="topicVersionRevision">Topic 2612 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17486055" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nonductal neoplasms of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25312765" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448665" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16030115" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Differences in survival by histologic type of pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703061" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26487581" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19690522" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18491401" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25291526" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25291526" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12039924" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20087335" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515795" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17312380" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Well-differentiated pancreatic nonfunctioning tumors/carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671766" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322345" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21388967" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27965134" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : National Rise of Primary Pancreatic Carcinoid Tumors: Comparison to Functional and Nonfunctional Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25984844" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17438169" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20623205" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365596" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22350605" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7686077" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management of non-functioning neuroendocrine tumours of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9202529" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11149582" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12417506" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16085691" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Endocrine pancreatic tumors: factors correlated with survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18506737" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20139156" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27553864" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The epidemiology of metastases in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066493" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26712231" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156937" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9423664" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Carcinoid metastases to the liver: role of triple-phase helical CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9574609" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067742" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490490" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8013189" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Imaging islet cell tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231629" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Identification of unknown primary tumors in patients with neuroendocrine liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10671597" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644985" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8325191" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625361" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984627" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Transhepatic portal vein catheterization for localization of insulinomas: a ten-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1317506" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Localization of pancreatic endocrine tumors by endoscopic ultrasonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007228" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16231278" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25805462" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16915538" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8831579" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618505" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Endoscopic ultrasound-guided fine-needle aspiration cytology of pancreatic neuroendocrine tumors: a study of 48 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21964743" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604127" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616879" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31853990" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27660147" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25952736" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025982" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8944566" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12665686" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589762" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12021920" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2227278" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445232" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16967267" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22415420" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21709192" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26765964" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26765964" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27646952" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
